Acute Lymphocytic Leukemia Clinical Trials

126 clinical trials for Acute Lymphocytic Leukemia across international registries, including 15 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL) — RECRUITING · PHASE2
• CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies — RECRUITING · PHASE1
• Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors — RECRUITING · PHASE1
• Allo HSCT Using RIC and PTCy for Hematological Diseases — RECRUITING · PHASE2
• Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies — RECRUITING · PHASE1
• Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution — RECRUITING
• TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL — RECRUITING · PHASE1
• Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. — RECRUITING · PHASE1
• Pilot Imaging Study of Leukemia — RECRUITING · PHASE1
• The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen — RECRUITING
• Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood — RECRUITING · PHASE2
• Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) — RECRUITING · PHASE1
• BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL — RECRUITING · PHASE1
• Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia — RECRUITING · PHASE1
• A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors — RECRUITING · NA
• In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases — TERMINATED · NA
• A Study to Learn About the Safety of BESPONSA Injection in Pediatric Patients With Acute Lymphocytic Leukemia. — ACTIVE_NOT_RECRUITING
• Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies — COMPLETED · PHASE1
• Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy — ACTIVE_NOT_RECRUITING · PHASE2
• Cryopreserved MMUD BM With PTCy for Hematologic Malignancies — WITHDRAWN · PHASE1
• CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL — ACTIVE_NOT_RECRUITING · PHASE1
• Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy — ACTIVE_NOT_RECRUITING · PHASE1
• Clinical Study of Recombinant Anti-CD19m-CD3 Antibody Injection (A-319) — NOT_YET_RECRUITING · NA
• Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy — ACTIVE_NOT_RECRUITING · PHASE2
• BESPONSA Injection 1 mg Special Investigation — COMPLETED
• INCB018424 in Patients With Advanced Hematologic Malignancies — COMPLETED · PHASE2
• CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies — COMPLETED · PHASE1
• A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia — TERMINATED · PHASE1
• Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor — COMPLETED · PHASE2
• Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation — COMPLETED · PHASE1
• Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors — COMPLETED · PHASE1
• A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia — COMPLETED · PHASE1
• Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide — TERMINATED · PHASE2
• Expanded Access to Navitoclax — TERMINATED
• Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies — COMPLETED · PHASE1
• A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies — WITHDRAWN · PHASE1
• Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant — COMPLETED · PHASE1
• Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant — COMPLETED · PHASE2
• Allo HSCT Using RIC for Hematological Diseases — COMPLETED · PHASE2
• Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning — COMPLETED · PHASE2
• A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene — COMPLETED · PHASE1
• Reduced Intensity Conditioning Transplant Using Haploidentical Donors — COMPLETED · PHASE2
• Genetic Polymorphisms in Drug Induced Neuropathy in Children With ALL — OTHER
• CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia — OTHER · PHASE1
• Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis — COMPLETED · PHASE2
• Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT — COMPLETED · NA
• Nonmyeloablative Allogeneic Transplant — COMPLETED · NA
• Human Placental-Derived Stem Cell Transplantation — COMPLETED · PHASE1
• Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies — OTHER · PHASE1

Refine this search